Brief History of Remedica, a leading pharmaceutical company in the European Union

Remedica's History

2019

2019

    • Two Cyprus HR Awards
    • “National Winner” at the European Business Awards 2019
    • Cyprus Active Citizen Award
    • Golden Environment Protector Award
2018

2018

    • Included in the London Stock Exchange List of “1000 Companies to Inspire Europe”
    • National winner in the 2018 “European Business Awards”
    • Entevirem® (Entecavir) has been approved by the Pharmaceutical Services of the Ministry of Health of Cyprus and more registrations are pending.
    • Rezavir® (Darunavir) has received its first regulatory approval by the Pharmaceutical Services Department of the Ministry of Health of Cyprus.
    • Trinistem® (Efavirenz 600mg, Emtricitabine 200mg, Tenofovir Disoproxil Succinate 245mg) has received its first regulatory approval.
    • Refetib® (Gefetinib, 250mg, Film-Coated Tablets) has received its first regulatory approval.
    • Penopen® (Phenoxymethylpenicillin Potassium,1000mg, Film-Coated Tablets), and Penopen® (Phenoxymethylpenicillin Potassium, 800mg, Film-Coated Tablets) have received their first regulatory approval.
2017

2017

    • Nevalan®, a drug for acid related disorders, Entevirem®, an antiviral for systemic use, Rezavir®, an antiviral for systemic use, and Bradirem®, a cardiac therapy were registered successfully in Cyprus.
    • Remedica elected as the best Company in the Ascendis Health Group of Companies
    • Co-founded CSR Cyprus
2016

2016

Remedica became part of the Johannesburg-listed healthcare conglomerate Ascendis Health Ltd. As part of this development, Remedica integrated with the Ascendis Health Pharma-Med division and became an important and integral part of a stronger, international player.

2015

2015

  • Remedica won a place in the final top 10 best export companies across Europe (Ruban d’Honneur) at the European Business Awards.
  • The company was successfully inspected by the Iranian Authorities (IFDA)